Company Filing History:
2 out of 1,209 
2 out of 517 
2 out of 2,963 
Years Active: 2022-2025
Title: Innovations of Xia Bu in Cancer Research
Introduction
Xia Bu is a notable inventor based in Brookline, MA (US), recognized for his contributions to cancer research. He holds two patents that focus on the modulation of programmed death 1 (PD-1) signaling, which is crucial in the field of immunotherapy.
Latest Patents
His latest patents include a method of assessing the efficacy of a test agent for modulating PD-1 signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies. This invention is based on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1. It also encompasses immunoglobulins, polypeptides, nucleic acids, and methods for using these antibodies for diagnostic, prognostic, and therapeutic purposes. Another significant patent involves anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, along with methods of making and using these antibodies for similar applications.
Career Highlights
Xia Bu has worked with prestigious institutions such as Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. His work has significantly advanced the understanding of PD-1 signaling in cancer treatment.
Collaborations
He has collaborated with notable colleagues, including Gordon James Freeman and Vassiliki A. Boussiotis, who have also made significant contributions to cancer research.
Conclusion
Xia Bu's innovative work in the field of cancer research, particularly regarding PD-1 signaling, showcases his commitment to advancing therapeutic strategies. His patents reflect a deep understanding of immunology and its applications in medicine.